Craig-Hallum lowered the firm’s price target on Surgalign to $2 from $5 and keeps a Hold rating on the shares. Surgalign’s FY22 results fell short of expectations, but the pipeline for FY23 could position the company for a change of course in FY23 and beyond, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SRGA:
- Surgalign Holdings, Inc. Announces Fourth Quarter and Full Year 2022 Results
- Surgalign Holdings, Inc. (SRGA) Q4 Earnings Cheat Sheet
- Surgalign Schedules Fourth Quarter and Full Year 2022 Earnings Release for March 30, 2023
- Surgalign launches first major upgrade of HOLO Portal Surgical Guidance System
- Surgalign Launches Next Generation Software for its HOLO Portal™ Surgical Guidance System and Expands Surgical Tool Integration to Drive Use Case Adoption
